Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Conference News ACC 2015

ERICCA: Remote Ischemic Preconditioning Fails to Improve Long-Term Outcomes After CABG

Yael L. Maxwell

March 16, 2015

News Daily News

Los Antecentes de CABG Limitan el Éxito de las PCI por OTC en las Arterias Coronarias Nativas

January 27, 2014

News Daily News

Subestudio PLATO: El Ticagrelor se asocia a Menos Hemorragias, Infecciones y Muerte que el Clopidogrel tras CABG

September 27, 2012

News Daily News

Se Publica el TARGET-CABG: El Período de Espera al CABG depende de la Prueba de la Función Plaquetaria

Yael L. Maxwell

March 15, 2012

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.